

Product datasheet for TR313577

OriGene Technologies, Inc.9620 Medical Center Drive, Ste 200

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

CYP7B1 Human shRNA Plasmid Kit (Locus ID 9420)

Product data:

Product Type: shRNA Plasmids

Product Name: CYP7B1 Human shRNA Plasmid Kit (Locus ID 9420)

Locus ID: 9420

Synonyms: CBAS3; CP7B; SPG5A

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection: Format:

Retroviral plasmids

Components: CYP7B1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

9420). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 001324112, NM 004820, NM 004820.1, NM 004820.2, NM 004820.3, NM 004820.4,

BC029155, BC136574, BM729103, NM 004820.5

UniProt ID: <u>075881</u>

Summary: This gene encodes a member of the cytochrome P450 superfamily of enzymes. The

cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This endoplasmic reticulum membrane protein catalyzes the first reaction in the cholesterol catabolic pathway of extrahepatic tissues, which converts cholesterol to bile acids. This enzyme likely plays a minor role in total bile acid synthesis, but may also be involved in the development of

atherosclerosis, neurosteroid metabolism and sex hormone synthesis. Mutations in this gene

have been associated with hereditary spastic paraplegia (SPG5 or HSP), an autosomal

recessive disorder. [provided by RefSeq, Apr 2016]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our custom shRNA service.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).